# Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes

> **NCT04733508** · NA · UNKNOWN · sponsor: **Radboud University Medical Center** · enrollment: 28 (estimated)

## Conditions studied

- Diabetes Mellitus
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** 111In-DTPA-exendin-4
- **DRUG:** IRDye800CW-exendin-4

## Key facts

- **NCT ID:** NCT04733508
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-01
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2021-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04733508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04733508, "Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04733508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*